Psychiatric Times

12/02/2025

Today is 🫶

Check out this curated list of places where you can make a difference in psychiatry with your donations. Where are you donating today?
https://www.psychiatrictimes.com/view/this-giving-tuesday-give-back-to-psychiatry

12/02/2025

Our December theme: 2025 Wrap Up.

What did you learn in 2025? What was the most important psychiatric advancement in 2025? Do you have practice tips to offer your fellow mental health clinicians? Share with us! https://www.psychiatrictimes.com/view/presenting-our-december-theme-2025-wrap-up

11/27/2025

This season, we give thanks for the mental health professionals, researchers, and advocates who work tirelessly to support wellness and healing. 🦃💙
Wishing you peace and connection this Thanksgiving.

11/26/2025

Need CME credit? This holiday weekend, check out our latest CME article on the assessment and management of su***de risk in bipolar disorder: https://www.psychiatrictimes.com/view/through-the-peaks-and-valleys-assessing-and-addressing-su***de-risk-in-bipolar-disorder

11/19/2025

Jail diversion programs reduce recidivism, improve health outcomes, and are cost-effective compared with traditional incarceration. https://www.psychiatrictimes.com/view/breaking-the-cycle-jail-diversion-as-an-alternative-to-incarceration-for-individuals-with-co-occurring-disorders

11/19/2025

📣 A New Era in Clozapine Education
Are you confident prescribing clozapine?
Through a partnership between S&PAA and AAPP: Clozapine Education Modules, designed for busy prescribers who want expert, evidence-based answers—fast.
From “When do I start?” to “How do I manage side effects?”
Featuring expert, Megan Ehret, PharmD, MS, BCPP, FAAPP
Short, focused modules—each under an hour

🔗Don’t miss your chance to be the first to access this FREE learning series: https://hubs.li/Q03SF_5y0

&PAA

11/14/2025

The FDA has granted a label expansion for the deep transcranial magnetic stimulation system that makes the treatment available as an adjunct therapy for adolescents aged 15 to 21 years who have major depressive disorder.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

11/14/2025

Placebo treatments can yield clinically meaningful improvements across psychiatric disorders. A new study found the strongest effects in depression and anxiety, and the weakest effects seen in schizophrenia and OCD.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

11/13/2025

In the Vibrance-2 study, once-daily alixorexton met the dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared with placebo on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week 8.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

11/12/2025

Mentalization-based treatment for narcissism recommends a step-by-step trajectory of interventions, organized around the different types of mentalizing. Learn more in one of our November cover stories: https://www.psychiatrictimes.com/view/mentalization-based-treatment-a-promising-approach-for-pathological-narcissism

11/11/2025

Today, we honor and thank the brave men and women who have served our country.
Psychiatric Times recognizes the unique mental health challenges faced by veterans and remains committed to advancing education, research, and compassionate care for those who have sacrificed so much.

11/10/2025

In a phase 2b open-label extension study of AtaiBeckley's BPL-003 in patients with treatment-resistant depression, investigators found that a 12 mg dose of BPL-003 administered 8 weeks after a 0.3 mg, 8 mg, or 12 mg dose of BPL-003 was generally well-tolerated and provided additional rapid, clinically meaningful antidepressant effects, which were sustained for up to 8 weeks.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.